At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Lasmiditandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients With Migraine
In Brief
A Phase 1 clinical trial evaluating Lasmiditan for Migraine. Completed, enrolled 18 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, and includes 4 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan, Puerto Rico, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionJan 2020
Study CompletionFeb 2020
TodayJul 2026
First PostedJun 17, 2019
Enrollment StartJul 22, 2019
Primary CompletionJan 19, 2020
Study CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.0 years ago
Interventions
Lasmiditandrug
Administered orally.